N-羟基-6-[(2-苯基乙酰基)氨基]-1-苯并噻吩-2-甲酰胺 | 850072-36-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-羟基-6-[(2-苯基乙酰基)氨基]-1-苯并噻吩-2-甲酰胺
• 英文名称: 6-Phenylacetylamino-benzo[b]thiophene-2-carboxylic acid hydroxyamide
• 英文别名: N-hydroxy-6-(2-phenylacetamido)benzo[b]thiophene-2-carboxamide；N-hydroxy-6-[(2-phenylacetyl)amino]-1-benzothiophene-2-carboxamide
• CAS: 850072-36-5
• 化学式: C₁₇H₁₄N₂O₃S
• 分子量: 326.376
• InChiKey: ZZNJYJHJZHVNGK-UHFFFAOYSA-N

物化性质

• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,4-二硝基苯甲醛 在 palladium 10% on activated carbon N-甲基吗啉 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 123.0h， 生成 N-羟基-6-[(2-苯基乙酰基)氨基]-1-苯并噻吩-2-甲酰胺
  参考文献：
  名称：

  [EN] THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES
  [FR] DERIVES THIOPHENE ET BENZOTHIOPHENE D'ACIDE HYDROXAMIQUE

  摘要：

  公开号：

  WO2005034880A3

文献信息

• Histone deacetylase inhibitors
  申请人：Bressi C. Jerome

  公开号：US20050137234A1

  公开（公告）日：2005-06-23

  Histone deacetylase inhibitors and uses thereof are provided that have the general formula: Z-L-M wherein Z, L and M are as defined herein.

  提供了具有一般式Z-L-M的组织脱乙酰化酶抑制剂及其用途，其中Z，L和M的定义如本文所述。
• Thiophene and Benzothiophene Hydroxamic Acid Derivatives
  申请人：Miller A. Thomas

  公开号：US20070213392A1

  公开（公告）日：2007-09-13

  The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一种新型的羟胺酸衍生物，其具有苯并噻吩或噻吩骨架。这些羟胺酸化合物可用于治疗癌症。这些羟胺酸化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物对于治疗具有肿瘤细胞增殖特征的患者是有用的。本发明的化合物还适用于预防和治疗TRX介导的疾病，例如自身免疫性、过敏性和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，例如神经退行性疾病。本发明还提供了包含羟胺酸衍生物的药物组合物和这些药物组合物的安全剂量方案，其易于遵循，并且在体内产生治疗有效量的羟胺酸衍生物。
• Benzo[b]thiophene-based histone deacetylase inhibitors
  作者：David J. Witter、Sandro Belvedere、Liqiang Chen、J. Paul Secrist、Ralph T. Mosley、Thomas A. Miller

  DOI：10.1016/j.bmcl.2007.05.091

  日期：2007.8

  Benzo[b]thienyl hydroxamic acids, a novel class of historic deacetylase (HDAC) inhibitors, were identified via a targeted screen of small molecule hydroxamic acids. Various substitutions were explored in the C5- and C6-positions of the benzo[b]thiophene core to characterize SAR and develop optimal inhibitors. It was determined that substitution at the C6-position of the benzo[b]thiophene core with a three-atom spacer yielded optimal HDAC I inhibition and anti-proliferative activity in murine erythroleukemia (SC-9) cells. (c) 2007 Elsevier Ltd. All rights reserved.
• THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES
  申请人：Aton Pharma, Inc.

  公开号：EP1677731A2

  公开（公告）日：2006-07-12
• EP1677731A4
  申请人：——

  公开号：EP1677731A4

  公开（公告）日：2009-05-06